Danielle M. Brander, MD, Duke Cancer Institute
Advertisement
Articles by Danielle M. Brander, MD, Duke Cancer Institute
Advertisement
Latest Updated Articles
Therapeutic Sequencing in Relapsed/Refractory CLLPublished: January 8th 2021 | Updated:
Allogeneic Transplantation for CLLPublished: January 8th 2021 | Updated:
Frontline CLL Treatment: Addressing Unmet NeedsPublished: January 8th 2021 | Updated:
Selecting Frontline Therapy to Treat CLLPublished: January 8th 2021 | Updated:
Frontline CLL Treatment With Fixed-Duration RegimensPublished: January 8th 2021 | Updated:
Minimal Residual Disease in CLLPublished: January 8th 2021 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Daratumumab and Hyaluronidase Plus VRd for Newly Diagnosed Multiple Myeloma
2
PD-L1 Expression Is More Predictive of Response to Pembrolizumab on Metastatic Sites in High-Grade Serous Ovarian Cancer
3
Lurbinectedin-Based Triplet Shows Clinical Benefit in Advanced Soft Tissue Sarcoma
4
Ultra-Sensitive ctDNA and CSF Liquid Biopsy May Refine Monitoring and Adaptive Trial Designs in Metastatic Breast Cancer
5